The headline reads as positive (34% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The broader analysis agrees with the good news.
Stocks › CVS
CVS Health Corp (CVS) stock analysis
WEAK BUY 20% confidence · analysed Sep 1, 2026
This analysis is from Sep 1, 2026 and may be out of date.
On Sep 1, 2026, our model rated CVS Health Corp (CVS) WEAK BUY with 20% confidence at a price of $96.62. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryHealthcare Plans
Market cap123580000000.0
Analysed price$96.62
Technical picture
The 14-day RSI is 59, showing healthy upward momentum without being stretched.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is only 0.1x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $83.21 and the swing low is $68.48; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 0.25, which looks cheap relative to its expected growth.
The company reports a profit margin of 1.2% and revenue growth of +7.1%.
In its latest quarter it earned $2.58 per share, which beat the $1.85 analysts expected, with revenue +7.3% year over year.
Wall Street's average rating is 1.4 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $116.08.
The next earnings report is expected around Oct 28, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $97.22, a target of $100.37 (+3.2%) and a stop-loss at $93.11 (-4.2%).
That is a reward-to-risk ratio of about 0.8 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Sep 11, 2026 whatever the price does.
Entry$97.22
Target$100.37
Stop-loss$93.11
Reassess bySep 11, 2026
Research notes
CVS’s bull case is that earnings and guidance are improving, with Q2 adjusted EPS of $2.58 beating estimates, revenue up 7.3% year over year, and 2026 EPS guidance raised to $7.90–$8.10; analysts remain broadly positive, with consensus targets around $107–$116 and several buy ratings. The bear case is that the market is focused on 2027, where CVS’s first EPS view of at least $8.44 was seen as not meaningfully above expectations, and management flagged Caremark membership loss next year, raising concerns about margin pressure and slower growth. A major recent catalyst was the Aug. 5 earnings report: despite a strong beat and higher 2026 guidance, the stock fell about 6% because investors reacted negatively to the 2027 outlook and Caremark commentary. More recently, CVS has also gotten a modest sentiment lift from coverage changes tied to obesity drugs, including restored coverage of Lilly’s Zepbound and coverage for a newly approved obesity pill, which helped the stock trade higher in late August.
The model's one-paragraph read
Leans BUY — composite score +0.20 (WEAK BUY). Technicals: RSI 59.27, MACD bullish, price below SMA50. Fundamentals: PEG 0.25, margin 1.2%, revenue growth 7.1%. Financial results: YoY revenue +7.3%, last EPS surprise +39.5%, next earnings 2026-10-28. Smart Money Concepts: BOS bullish (trend continuation). FinGPT news read: neutral. Internet research: CVS’s **bull case** is that earnings and guidance are improving, with Q2 adjusted EPS of $2.58 beating estimates, revenue up 7.3% year over year, and 2026 EPS guidance raised to $7.90–$8.10; analysts remain broadly positive, with consensus targets around $107–$116 and several buy ratings. The **bear case** is that the market is focused on 2027, where CVS’s first EPS view of at least $8.44 was seen as not meaningfully above expectations, and management flagged Caremark membership loss next year, raising concerns about margin pressure and slower growth. A major **recent catalyst** was the Aug. 5 earnings report: despite a strong beat and higher 2026 guidance, the stock fell about 6% because investors reacted negatively to the 2027 outlook and Caremark commentary. More recently, CVS has also gotten a modest sentiment lift from coverage changes tied to obesity drugs, including restored coverage of Lilly’s Zepbound and coverage for a newly approved obesity pill, which helped the stock trade higher in late August. Suggested levels: entry $97.22, target $100.37, stop-loss $93.11, exit by 2026-09-11 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for CVS
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Sep 1, 2026 | WEAK BUY | 20% | $96.62 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on CVS
Oct 13, 2026 · CVS agrees to $315M DOJ settlement, enhanced DEA prescription oversight
- Oct 13, 2026: CVS agrees to $315M DOJ settlement, enhanced DEA prescription oversight (Investing.com)
- Oct 13, 2026: CVS Agrees to $315M Settlement in Department of Justice Opioid Lawsuit Without Admitting Fault (First for Money)
- Oct 13, 2026: CVS Health Unit to Pay $315 Million to Resolve Illegal Opioid Prescription Claims (The Wall Street Journal)
Other Healthcare stocks we cover
DVA · EVH · FTRE · HALO · HUM · IART · ICLR · IRWD · JNJ · KMDA · LH · LLY
Frequently asked questions
Is CVS a buy right now?
As of Sep 1, 2026, our automated model rates CVS Health Corp (CVS) WEAK BUY with 20% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for CVS?
The model's most recent plan targets $100.37 with a stop-loss at $93.11, from an entry near $97.22.
When does CVS Health Corp report earnings next?
The next earnings report is expected around Oct 28, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.